The Three-Body Problem of Lipid Manufacturing: Synthesis, Purity, and Scale
335 – 25 Street S.E. Calgary, Alberta, Canada T2A 7H8 www.northernrna.com Overview The clinical efficacy of lipid nanoparticle (LNP) systems is a direct function of their multicomponent lipid architecture. Each constituent, ionizable, phospholipid, PEG-lipid, and cationic lipid, fulfills a precise structural and functional role, with overall formulation performance being critically dependent on the physicochemical properties […]
Delivering the Promise: Building Scalable, Intelligent Platforms for mRNA–LNP Therapeutics and Vaccines
335- 25th Street S.E. Calgary, Alberta, Canada T2A 7H8 www.northernrna.com Messenger RNA (mRNA) therapeutics and vaccines have reshaped the landscape of modern medicine, offering unprecedented flexibility in addressing infectious diseases, cancer, and rare genetic disorders. Lipid nanoparticle (LNP) delivery systems are central to this success, protecting fragile mRNA from degradation and enabling efficient intracellular delivery. […]
Northern RNA Inc. has been recognized by BioTalent Canada as an I.D.E.A.L. Bioscience Employer for 2025-2026
Calgary, January 27, 2026 – Northern RNA Inc. has once again been recognized by BioTalent Canada as an I.D.E.A.L. Bioscience Employer™ for 2025-2026, marking the third consecutive year the organization has received this distinction. This continued recognition reflects Northern RNA’s ongoing commitment to embedding IDEA best practices, Inclusivity, Diversity, Equity, and Accessibility, into its culture and […]
Northern RNA and Genvax Technologies Announce Strategic Collaboration Agreement
Posted on 3 December 2025 by Northern RNA CALGARY, Canada and AMES, United States – 3 December 2025 – Northern RNA, a Canadian-based contract development and manufacturing organization (CDMO) specializing in GMP production of RNA-based therapeutics and Genvax Technologies, a startup animal health company specializing in custom prescription livestock vaccines have today announced a strategic […]
Todd Howren, PhD, Joins Northern RNA as Chief Commercial Officer (CCO)
Posted on 10 June 2025 by Northern RNA CALGARY, CANADA – 10 June 2025 – Northern RNA, a leading contract drug manufacturing organization (CDMO) specializing in GMP manufacturing of RNA-based vaccines and therapeutics, today announced that Todd Howren will be joining Northern RNA as Chief Commercial Officer (CCO). “We are thrilled to welcome Todd Howren […]
Dr. John Ballantyne, PhD, successful biotechnology executive and founder joins Northern RNA Board of Directors
Posted on 27 March 2025 by Northern RNA CALGARY, CANADA – 27 March 2025 – Northern RNA, a leading contract drug manufacturing organization (CDMO) specializing in GMP manufacturing of RNA-based vaccines and therapeutics, today announced the appointment of Dr. John Ballantyne, PhD, to its Board of Directors “We are pleased to welcome John Ballantyne […]
Northern RNA Inc. awarded grant funding from Alberta Innovates to support the development of next generation lipids
Posted on March 10, 2025 by Northern RNA CALGARY, Alberta (March 10, 2025) – Northern RNA today announced that they have been awarded grant funding from Alberta Innovates to support the development of advanced manufacturing processes for next generation lipids. The next generation lipid manufacturing effort addresses a critical gap in the global supply of […]
Northern RNA and Epitopea Announce Strategic Collaboration Agreement
Northern RNA and Epitopea Announce Strategic Collaboration Agreement Posted on 24 February 2025 by Northern RNA CALGARY, CANADA and MONTREAL CANADA – February 24, 2025 – Northern RNA, a contract drug manufacturing organization (CDMO) specializing in GMP manufacturing of RNA-based vaccines and therapeutics, and Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, today announced they have entered […]
Northern RNA Inc. Signs Memorandum of Understanding with Alexander Chemical L.P.
Northern RNA Inc. Signs Memorandum of Understanding with Alexander Chemical L.P. Posted on February 03, 2025 by Northern RNA CALGARY, Alberta February 3, 2025 – Northern RNA Inc. is excited to announce that we have signed a Memorandum of Understanding (MOU) with Alexander Chemical L.P. (ACLP), a majority First Nations owned and Canadian owned company. […]
Northern RNA and Kaster Technologies announce Memorandum of Understanding
Calgary, Alberta October 28, 2024 – Northern RNA Inc. is excited to announce the signing of a Memorandum of Understanding (MOU) with Kaster Technologies Inc., a cutting-edge Canadian company specializing in digital tools for optimizing drug and life science manufacturing. This MOU marks an exciting milestone for Northern RNA as we seek to strengthen our […]